https://www.inderes.fi/videos/xbrane-biopharma-webcast-with-teleconference-q423
Xbrane Biopharma, Webcast with teleconference, Q4'23 - Inderes
xbrane biopharmawebcastteleconference
https://www.finanzen.net/aktien/xbrane_biopharma_cons_of_50-aktie
XBRANE BIOPHARMA CONS OF 50 AKTIE | Aktienkurs | SE0021515111 | A403LL | News | finanzen.net
XBRANE BIOPHARMA CONS OF 50 AKTIE und aktueller Aktienkurs. Nachrichten zur Aktie Xbrane Biopharma AB Cons Of 50 Shs + 9 Wts TO1 | A403LL | SE0021515111
xbrane biopharmaconsaktienewsfinanzen
https://quartr.com/events/xbrane-biopharma-xbrane-q2-2025_3eOLi2ew
Xbrane Biopharma (XBRANE) Q2 2025 Summary | Quartr
Summary of Xbrane Biopharma (XBRANE) Q2 2025, combining transcript, slides, and related documents.
xbrane biopharmasummaryquartr
https://www.home.saxo/nl-be/markets/stocks/xbrane-xome
Xbrane Biopharma AB aandeel | Saxo Bank
Xbrane Biopharma AB is a biotechnology company that develops biosimilars.
xbrane biopharmasaxo bankab
https://convention.bio.org/participating-companies/xbrane-biopharma
Xbrane Biopharma - BIO International Convention 2026
bio international conventionxbrane biopharma
https://sevva.ai/page/company-profile/Xbrane%20Biopharma%20AB
Xbrane Biopharma AB ESG AI Company Profile - Sevva AI
Xbrane Biopharma AB ESG Rating and Company Profile. Powered by Sevva AI. Ratings use UN SDG methodology and NLP to find information in pubilc disclosures and...
xbrane biopharmaai companyabesgprofile
https://nordiclifescience.org/xbrane-biopharma-accelerates-development-of-xdivane/
Xbrane Biopharma accelerates development of Xdivane - NLS
Apr 23, 2019 - Xbrane Biopharma recently initiated the phase III trial in the US with Xlucane, a ranibizumab (Lucentis) biosimilar candidate.
xbrane biopharmadevelopmentnls
https://www.chemdiv.com/company/media/pharma-news/2016/xbrane-signs-deal-helvetic-biopharma-lead-ranibizumab-biosimilar-xlucane/
Xbrane Signs Deal With Helvetic BioPharma for its Lead Ranibizumab Biosimilar,...
Xbrane Signs Deal With Helvetic BioPharma for its Lead Ranibizumab Biosimilar, Xlucane
signsdealbiopharmaleadbiosimilar